Cargando…

Transcriptome-based stemness indices analysis reveals platinum-based chemo-theraputic response indicators in advanced-stage serous ovarian cancer

Serous ovarian cancer (SOC) is a main histological subtype of ovarian cancer, in which cancer stem cells (CSC) are responsible for its chemoresistance. However, the underlying modulation mechanisms of chemoresistance led by cancer stemness are still undefined. We aimed to investigate potential drug-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Xinwei, Liu, Qingyu, Huang, Jie, Diao, Ge, Liang, Zhiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806806/ https://www.ncbi.nlm.nih.gov/pubmed/34266348 http://dx.doi.org/10.1080/21655979.2021.1939514

Ejemplares similares

Theological Theraputics
Publicado: (1879)

Tizoxanide as a novel theraputic candidate for osteoarthritis
por: Ni, Bowei, et al.
Publicado: (2023)

Prediction of chemo-response in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2016)

Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
por: Qi, Xin, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio is associated with sensitivity to platinum-based chemotherapy and prognosis in patients with advanced serous ovarian carcinoma
por: Fukuda, Takeshi, et al.
Publicado: (2021)

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
por: Chowdhury, Shrabanti, et al.
Publicado: (2023)

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
por: Li, Yuan, et al.
Publicado: (2021)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
por: BRACHOVA, PAVLA, et al.
Publicado: (2014)

Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer
por: Hou, Shunyu, et al.
Publicado: (2018)

Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers
por: Mesquita, Katia A., et al.
Publicado: (2021)

MAGE-A10 Protein Expression in Advanced High Grade Serous Ovarian Cancer Is Associated with Resistance to First-Line Platinum-Based Chemotherapy
por: Lisica Šikić, Nataša, et al.
Publicado: (2023)

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks
por: Yu, Kun-Hsing, et al.
Publicado: (2020)

3468 Predictive biomarkers of platinum-based chemotherapy response in Puerto Rican Hispanics with high-grade serous ovarian cancer.
por: Reyes-Gonzalez, Jeyshka M., et al.
Publicado: (2019)

YKL-40 in the diagnosis, prediction of prognosis, and platinum sensitivity in serous epithelial ovarian cancer
por: Kahramanoğlu, İlker, et al.
Publicado: (2018)

Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2019)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
por: Abdallah, Reem, et al.
Publicado: (2023)

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer
por: Weberpals, Johanne I., et al.
Publicado: (2021)

Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma
por: Liu, Gang, et al.
Publicado: (2018)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Microarray-Based Oncogenic Pathway Profiling in Advanced Serous Papillary Ovarian Carcinoma
por: Trinh, Xuan Bich, et al.
Publicado: (2011)

Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia
por: Aluloski, Igor, et al.
Publicado: (2017)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
por: Wu, Huan, et al.
Publicado: (2020)

Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
por: Hwangbo, Suhyun, et al.
Publicado: (2021)

Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer
por: Tan, Jiahong, et al.
Publicado: (2021)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database
por: Li, Xiaoduo, et al.
Publicado: (2021)

Spleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy
por: Wen, Shu Wen, et al.
Publicado: (2015)

MDCT-Based Radiomics Features for the Differentiation of Serous Borderline Ovarian Tumors and Serous Malignant Ovarian Tumors
por: Yu, Xin-ping, et al.
Publicado: (2021)

Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy
por: Boyraz, Gökhan, et al.
Publicado: (2017)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer
por: Silva, Vera L., et al.
Publicado: (2021)

Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer
por: Zheng, Mingjun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_20mapnv2hci6vbcuqei32h5udp